Pharmacy benefits manager CVS Health has warned that the new PCSK9 inhibitor class of cholesterol-lowering drugs poses an unprecedented challenge to the US healthcare system. In a blog post ...
“Statins and PCSK9 inhibitors are phenomenal meds and we have so much evidence that they can reduce risk, but we see a huge gap in patients receiving them,” says Amit Khera, vice president of ...
Inhibitors of LDL synthesis, lomitapide and mipomersen, are new therapeutic options. PCSK9 inhibitors are being evaluated in HoFH and seem to be effective if there is residual receptor activity.
AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes ...
In the past few years, pharmaceutical companies have produced a class of drugs that lower cholesterol by inhibiting a protein called PCSK9 in a new attempt to reduce the risk of heart disease, the ...
so they don’t have that same effect of causing liver damage. PCSK9 inhibitors are a new class of medications that may be available to patients to help reduce their cholesterol. By inhibiting a ...